Christopher Prentiss Net Worth

The estimated Net Worth of Christopher B Prentiss is at least $2.38 Milion dollars as of 22 March 2021. Mr. Prentiss owns over 2,422 units of Adamas Pharmaceuticals Inc stock worth over $1,192,040 and over the last 7 years he sold ADMS stock worth over $95,680. In addition, he makes $1,093,640 as Chief Financial Officer, Chief Accounting Officer oraz Principal Financial Officer and Principal Accounting Officer at Adamas Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Prentiss ADMS stock SEC Form 4 insiders trading

Christopher has made over 9 trades of the Adamas Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,422 units of ADMS stock worth $13,273 on 22 March 2021.

The largest trade he's ever made was selling 3,821 units of Adamas Pharmaceuticals Inc stock on 1 February 2021 worth over $24,302. On average, Christopher trades about 847 units every 61 days since 2017. As of 22 March 2021 he still owns at least 145,017 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Mr. Prentiss stock trades at the bottom of the page.

Christopher Prentiss biography

Christopher B. Prentiss serves as Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company. Prior to joining Adamas, Mr. Prentiss was the Vice President, Finance and Controller at InterMune, Inc., a biotechnology company, from June 2013 to March 2015, where he was responsible for the management of the accounting function. Prior to that, Mr. Prentiss was Senior Director, Controller at Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, from May 2012 to June 2013, where he was responsible for the accounting and tax functions. From June 2005 to May 2012, Mr. Prentiss was at MannKind Corporation where he served in a variety of finance roles, most recently as Senior Director, Controller. Prior to joining MannKind, Mr. Prentiss was a Senior Manager at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor’s of Science degree in Accounting from Loyola Marymount University, and a Masters of Business Administration from Indiana University. Mr. Prentiss is a CPA licensed in California.

What is the salary of Christopher Prentiss?

As the Chief Financial Officer, Chief Accounting Officer oraz Principal Financial Officer and Principal Accounting Officer of Adamas Pharmaceuticals Inc, the total compensation of Christopher Prentiss at Adamas Pharmaceuticals Inc is $1,093,640. There are 2 executives at Adamas Pharmaceuticals Inc getting paid more, with Neil McFarlane having the highest compensation of $2,080,640.

How old is Christopher Prentiss?

Christopher Prentiss is 45, he's been the Chief Financial Officer, Chief Accounting Officer oraz Principal Financial Officer and Principal Accounting Officer of Adamas Pharmaceuticals Inc since 2019. There are 11 older and no younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.

What's Christopher Prentiss's mailing address?

Christopher's mailing address filed with the SEC is 1 CASPER STREET, , DANBURY, CT, 06810.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney oraz William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Mr. Prentiss stock trades at Adamas Pharmaceuticals Inc i Mannkind Corp

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director